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Abstract
Background: In 2002, the MOREOB (Managing Obstetrical Risk Efficiently) obstetrical patient safety program was
phased-in across hospitals in Ontario, Canada. The purpose of our study was to evaluate the effect of the MOREOB
program on rates of adverse maternal and neonatal outcomes.
Methods: A retrospective cohort study, using province-wide administrative hospitalization data. We included
maternal and neonatal records between fiscal years 2002–2003 and 2013–2014, for deliveries taking place at the
67 Ontario hospitals where the MOREOB program was implemented between 2002 and 2012. After accounting for
institutional mergers and excluding very small hospitals, 55 hospitals (1,447,073 deliveries) were included.
Multivariable logistic and linear mixed effects regression analysis were used, accounting for secular trends, within
hospital correlation and over time correlation, and adjusting for a maternal comorbidity index, hospital annual birth
volume, and level of care.
The main outcome measure was a composite individual-level indicator of incidence of any adverse events, and a
hospital-level score, called the Weighted Adverse Outcome Score (WAOS) capturing both maternal and neonatal
adverse outcomes.
Results: Across the 12 years of follow up, there were 98,789 adverse maternal and neonatal outcomes, a rate of 6.
83 per 100 deliveries (6.66 per 100 occurring before, 6.91 per 100 during, and 6.84 per 100 after program
implementation). The multivariable analysis found no statistically significant decrease in adverse events associated
with program implementation (OR for adverse events after versus before =1.11 (95% CI: 1.06 to 1.17, change in mean
WAOS score after minus before =0.15 (− 0.36 to 0.67)).
Conclusions: We did not find a reduction in the incidence of maternal and neonatal adverse outcomes associated
with the MOREOB program, and small yet statistically significant increases in some adverse events were observed.
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Background
In high-resource settings such as Canada, maternal and
neonatal adverse events during labour and birth are rela-
tively rare [1, 2]. Yet, when poor outcomes occur they
have the potential to cause serious long term conse-
quences for both mother and infant, and to be extremely
costly for families and insurers [3–5]. For this reason, a
number of obstetrical patient safety programs have been
designed, with the goal of reducing adverse maternal
and neonatal events [4–7].
In 2001, the Society of Obstetricians and Gynaecolo-
gists of Canada developed a program to improve patient
safety. The Managing Obstetrical Risk Efficiently (MOR-
EOB) program was initially pilot-tested in the Canadian
province of Ontario in 2002, and subsequently expanded
across Canada and elsewhere [8]. In 2007, the Society of
Obstetricians and Gynaecologists of Canada partnered
with the Healthcare Reciprocal of Canada to form Salus
Global, the organization that is now responsible for the
administration of the MOREOB program [8].
MOREOB is a patient safety, professional development
and performance improvement program for caregivers
and administrators in hospital obstetric units. It aims to
improve patient safety and reduce adverse events,
improve communication and teamwork and foster
evidence-based obstetrical care [9]. The program is of-
fered in three modules over a three-year period [8]. It
has been reported that participation in the MOREOB
program results in positive changes in workplace envir-
onment and safety culture [8], and increases the clinical
knowledge of participants [8]. A recently published study
using health insurer data from Ontario, Canada found
decreases in frequency and costs associated with report-
able events for the health insurer [10]. In addition, an
evaluation of clinical outcomes in the Canadian province
of Alberta reported a statistically significant reduction in
3rd and 4th degree perineal lacerations following imple-
mentation of Module 1 of the program, which was sus-
tained across all modules, as well as a significant
reduction in severe neonatal morbidity following Mod-
ules 2 and 3 [11]. There were no statistically significant
differences in rates of other clinical outcomes such as
fetal mortality, maternal infection or postpartum
hemorrhage; however, the study was likely not suffi-
ciently powered to detect changes in these infrequent
outcomes [11]. While there were numerous strengths of
the Alberta evaluation, there were also several limita-
tions, including the use of a simple before-and-after
study design and the short follow-up period which lim-
ited inference on program impact over the longer term.
Between 2002 and 2012, 67 Ontario hospitals adopted
the MOREOB program, and as of 2014, 63 of these had
completed the three modules. As part of a larger
mixed-methods evaluation of the MOREOB program, we
report here the results of an analysis assessing the effect
of implementation of the MOREOB program on rates of
adverse maternal and neonatal outcomes in the province
of Ontario using a retrospective cohort study.
Methods
Study design
MOREOB program implementation over the 12-year
study period, for each included hospital, is presented in
Fig. 1. Designing a robust evaluation of the MOREOB
program implementation was challenging for several
reasons, including the staggered implementation times
across the hospitals and the long and variable program
implementation phases [12–14]. We approached our
analysis using a quasi-experimental retrospective cohort
design with analysis based on the approach used for
stepped wedge trials. The stepped wedge is a type of
study design which can be used to evaluate interventions
implemented in phases at different points over time [15,
16]. In stepped wedge studies, outcomes are assessed re-
peatedly before and after implementation, and the overall
effectiveness of the intervention is determined by compar-
ing data points in the post-intervention section of the
wedge, to those in the pre-intervention section.
Study population
Initially, the 67 hospitals that implemented the MOREOB
program prior to 2012 were included. The study popula-
tion was comprised of the mother-newborn dyads born
at these hospitals between fiscal years 2002–2003 and
2013–2014.
In preparing the dataset for analysis, we accounted for
hospital mergers and closures over the course of the 12
years of follow up, which decreased the number of institu-
tions from 67 to 63. To avoid instability in the multivari-
able analysis, we subsequently excluded the 8 institutions
with annual birth volumes less than 250. Thus, 55 institu-
tions were included in our final analysis.
Data sources
We obtained a 12-year dataset of maternal-newborn
hospitalization records from the Canadian Institute for
Health Information’s (CIHI) Discharge Abstract Data-
base (DAD) for Ontario hospitals between April 1, 2002
and March 31, 2014 (i.e., fiscal years 2002–2003 to
2013–2014, inclusive). The DAD includes hospital separ-
ation abstracts submitted by all acute care hospitals in
Ontario. Each hospital abstract contains demographic
information, medical diagnoses including most respon-
sible diagnosis and 24 secondary diagnoses, interven-
tions received, length of hospital stay, vital disposition at
time of discharge and other data elements. Medical diag-
noses are coded using the Canadian implementation of
the International Classification of Diseases, 10th Revision
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(ICD-10-CA) from 2002 to 2003 to the present. The DAD
captures over 98% of all births, including all live birth and
stillbirth events occurring in Ontario hospitals through
the maternal record. In addition, there are separate re-
cords for live born neonates and stillbirths that capture
relevant morbidities, diagnoses and medical procedures.
We linked maternal and newborn abstracts together via
an encrypted maternal-newborn chart number [17].
Primary outcomes
We analyzed two previously-developed measures of ob-
stetric patient quality of care: a composite individual-
level indicator of incidence of any adverse maternal or
neonatal events, and a hospital-level score, called the
Weighted Adverse Outcome Score (WAOS). Both mea-
sures capture maternal and neonatal outcomes, and were
developed through repeated consultation with leaders in
nursing, obstetrics and anesthesia, among others [18].
The decision to use these two composite indices was
made for several reasons. Using previously-developed
measures facilitates comparison between our study and
previously published research [5, 6, 18–20]. Further, the
MOREOB program is comprehensive and multifaceted,
and could affect a number of maternal and newborn
outcomes. Therefore, using composite scores would bet-
ter capture the potential impact of the program. Note
that several modifications were required, most import-
antly the omission of the Apgar score, as it was not
available in the hospitalization database.
The composite individual-level indicator of adverse
event occurrence was based on the Adverse Outcome
Index (AOI), a composite score designed to capture the
quality of obstetrical care defined as “the number of de-
liveries complicated by one or more of the identified
outcomes divided by the total number of deliveries” [18].
We modified the AOI for our analysis (henceforth,
mAOI), and used it as a binary individual-level indicator,
rather than as a proportion calculated at the monthly
and hospital level, where a ‘1’ indicates the presence of
any component of the AOI and a ‘0’ indicates no com-
ponents had occurred for that individual. We decided to
use an individual-level analysis for the mAOI to allow
for unequal weighting based on hospital birth volume.
The mAOI captures the number of deliveries affected by
one or more of the adverse events included in the indi-
cator (see Table 2 and Additional file 1). The WAOS
additionally accounts for the severity of these events, by
assigning weighted scores to each event (Table 2).
Fig. 1 Program implementation timing by month, at 55 hospitals, Ontario, Canada, 2002 to 2014
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Further, because the weights are summed, both the
severity and number of events contribute to the score.
For example, maternal death is assigned the highest
score at 750 points per event, and 3rd or 4th degree
perineal tears are assigned the lowest, at 5 points per
event. If a delivery is complicated by multiple events,
their scores are summed [18]. The weighted sums are
then divided by the number of deliveries that took
place during a particular time period (e.g., per
month).
Dataset preparation
The timing of implementation for each hospital was
divided into segments based on program implementa-
tion: the pre-implementation period, the implementa-
tion period which included implementation time for
each of the three MOREOB modules, and the post-im-
plementation period. Two different datasets were pre-
pared, one for each outcome. The mAOI was defined
as described above and analyzed at the individual
level, and the WAOS was defined at the level of the
hospital, as the sum of all the weighted composite
scores, divided by the number of deliveries that oc-
curred in that hospital. Therefore, the analysis of the
WAOS required the creation of a dataset aggregated
by month and hospital.
The components of the composite indices were coded
from the ICD-10-CA and CCI (Canadian Classification
of Health Interventions) codes in the DAD, after review-
ing published lists of codes used for maternal-newborn
research using the DAD [19, 21–23]. The codes used for
our study, along with additional information about the
components, can be found in Additional file 1. Compo-
nents of the mAOI were modified based on the informa-
tion that was available in the DAD dataset. Specifically,
the Apgar score was unavailable and, therefore, not in-
cluded, and the data quality of 3rd degree perineal tears
was found to be problematic and therefore our compo-
nent was restricted to 4th degree perineal tears. Infor-
mation on the timing of module implementation for
each hospital was obtained from Salus Global.
Statistical analyses
Descriptive analyses
We used descriptive summary statistics to examine the
distribution of study variables at the hospital level.
Monthly time series plots of crude rates of study out-
comes (mAOI, WAOS and component outcomes) over
the 12-year study period were graphed by actual calen-
dar time (see Additional file 2).
Multivariable regression analyses
The mAOI was specified as the dependent variable and
analyzed at the individual woman-level using random
effects logistic regression, estimated using restricted
pseudo-likelihood estimation. MOREOB program imple-
mentation, coded as a step function taking the value 0
before implementation, increments of 0.25 with each
subsequent module, and 1 after completion of all mod-
ules, was included as a fixed effect. To account for the
underlying secular trend, (i.e., natural changes that occur
over time [24]), time was modeled as a restricted cubic
spline with five knots. Level of care, annual birth vol-
ume, and an obstetric comorbidity index [25] were also
included as fixed effects. The previously developed and
validated obstetric comorbidity index [25, 26] has been
found to predict severe maternal morbidity and mortal-
ity and includes more than 20 maternal comorbidities
and conditions that increase the risk of adverse preg-
nancy outcomes [25, 26]. To allow individual hospitals
to deviate randomly from the secular trend, random in-
tercepts and coefficients for time were specified for each
hospital. The regression coefficient for MOREOB pro-
gram implementation was exponentiated to yield an ad-
justed odds ratio (aOR) for the effect of program
implementation. This odds ratio compares the odds of
an adverse event for a woman in a hospital after pro-
gram implementation, to that of a woman in the same
hospital before implementation. Three important as-
sumptions of our model are that, after adjusting for
covariates, there are no systematic differences in
pre-implementation levels and trends across hospitals;
that the effect of the intervention is constant over
time (i.e., the models yield an estimate of the time-aver-
aged hospital-specific effect of the intervention); and there
is a gradient effect of the implementation across all mod-
ules, meaning a constant increase from the first to last
modules.
The WAOS was analyzed at the hospital-level using
mixed effects linear regression, estimated using re-
stricted maximum likelihood estimation. Fixed and ran-
dom effects were as described for the analyses of the
mAOI, with the exception that the comorbidity index
was aggregated to the level of the hospital in each
month. The regression coefficient for the MOREOB pro-
gram implementation variable yields an estimate of the
difference between the mean score post-implementation
and the mean score pre-implementation.
For both outcomes, the fitted secular trend was ob-
tained from the model and displayed graphically with
the covariates (hospital level and annual birth volume,
and comorbidity index) set to their mean values in
the study sample.
Secondary analyses included separate models for indi-
vidual components of the composite score, and examining
sensitivity due to misspecification of the secular trend by
specifying time as a categorical (rather than continuous)
variable. Also, between-hospital heterogeneity in the effect
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of the program was allowed for, by adding a random effect
for program implementation defined at the level of the
hospital. All analyses were carried out using SAS v. 9.4.
Results
The hospital sample was comprised of 12 level 1, 37
level 2 and 6 level 3 hospital sites, with 16 sites having
annual birth volumes less than 1000, 32 sites having an-
nual birth volumes between 1001 and 4000, and 7 sites
with annual birth volumes greater than 4000 (see
Additional file 3). A description of the study sample is
presented in Table 1. The sample was restricted to
women with singleton pregnancies. Overall, the study
sample included 1,447,073 deliveries at the 55 hospitals,
with 328,864 (22.7%) taking place before MOREOB was
implemented, 556,550 (38.5%) taking place during im-
plementation, and 561,659 (38.8%) taking place after.
It took hospitals on average 11.3 months to complete
the first module, 17.2 months to complete the second
and 25 months to complete the third. As indicated by
the standard deviations and interquartile ranges, there
was in fact a great deal of variability between hospital
sites with respect to amount of time taken to complete
the program, and program completion took longer than
the 3 years that has been reported [9].
Table 2 presents the occurrence of adverse events
across the 12 years of follow up. There were 98,789 ad-
verse events, for a rate of 6.83 per hundred deliveries,
with 21,898 (rate of 6.66%) events occurring before
MOREOB implementation, 38,462 (rate of 6.91%) occur-
ring during implementation, and 38,429 (rate of 6.84%)
occurring after. The most frequent adverse outcome was
neonatal intensive care unit (NICU) admission for at
least 2 days for infants with a birth weight of 2500 g or
more, which had a rate of 4.22% (n = 61,079). The least
frequent event was maternal death, with a rate of 0.005%
(n = 69).
Table 3 presents the results of the multivariable re-
gression analyses of the association between MOREOB
implementation and adverse maternal and neonatal
events when time was modelled using a restricted cubic
spline. This model revealed no evidence of improve-
ments in adverse events after MOREOB implementation.
In fact, for the mAOI, there was a small increase in the
odds of an adverse event in the post-MOREOB time
period compared with the pre-MOREOB time period
(aOR = 1.11 95% CI: 1.06 to 1.17).
In the analyses of individual components of the com-
posite scores (Table 3), the MOREOB program was asso-
ciated with increases in maternal unanticipated operative
procedures (aOR = 1.21, 95% CI: 1.05 to 1.39) and 4th
degree tear (aOR = 1.36, 95% CI: 1.11 to 1.65), and NICU
admission (aOR = 1.24, 95% CI: 1.17 to 1.32). While not
statistically significant at the conventional 5% level, the
results suggest an association with decreased maternal
blood transfusions (aOR = 0.83 (95% CI: 0.69 to 1.00))
and neonatal birth trauma (OR = 0.91 (95% CI: 0.75 to
1.10)). Maternal death and uterine rupture were not ana-
lyzed separately due to low frequency of events.
The modelled secular trends for the mAOI and
WAOS are presented graphically in Additional file 4.
These plots display how the mAOI and WAOS vary over
time, even in the absence of the MOREOB program.
There is evidence that both outcomes are decreasing
until the start of fiscal year 2008, at which time the rates
level off or slightly increase. These trends support our
choice to model time using a restricted cubic spline,
which allows for more flexibility in accounting for the
effects of secular trends on our outcomes. Results of the
secondary analyses with time modeled categorically are
presented in Additional file 5.
Table 1 Study sample characteristics of deliveries occurring in
55 institutions in Ontario, Canada, n = 1,447,073
Variable





> 4000 418,119 (28.9)









Timing of MOREOB participation at time of delivery, n (%)
Before start of MOREOB program 328,864 (22.7)
During Module 1 114,175 (7.9)
During Module 2 176,581 (12.2)
During Module 3 265,794 (18.4)
Post-MOREOB 561,659 (38.8)
Duration of hospital participation in each module in months, mean (SD),
Q1 to Q3
Module 1 11.3 (3.2), 9 to 12
Module 2 17.2 (4.8), 14 to 19
Module 3 25.0 (9.0), 16 to 33
Total 53.5 (10.9), 44 to 64
MOREOB Managing Obstetrical Risk Efficiently
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Discussion
Principal findings
In our analysis of adverse maternal and neonatal out-
comes in 55 Ontario hospitals enrolled in the MOREOB
program prior to 2012, we found no evidence of im-
provements in either of the composite indices after
MOREOB implementation. In fact, there was a small in-
crease in the occurrence of adverse events as captured
by the mAOI. In subanalyses with individual components
of the composite indices, we found small but statistically
significant increased odds of maternal unanticipated op-
erative procedures, 4th degree tears, and NICU admission;
Table 2 Components and total scores for the Adverse Outcome Index and Weighted Adverse Outcome Score
Variable Full Sample
n = 1,447,073






n(%) n(%) n(%) n(%)
Maternal death 69 (0.00) 750 51,750 14 (0.00) 30 (0.01) 25 (0.00)
Uterine rupture 516 (0.04) 100 51,600 106 (0.03) 192 (0.03) 218 (0.04)
Maternal admission to ICU 3566 (0.25) 65 231,790 714 (0.22) 1406 (0.25) 1446 (0.26)
Unanticipated operative procedure 11,081 (0.77) 40 443,240 2112 (0.64) 4168 (0.75) 4801 (0.85)
Blood transfusion 7880 (0.54) 20 157,600 2069 (0.63) 3121 (0.56) 2690 (0.48)
4th degree tearb 5187 (0.36) 5 25,935 1169 (0.36) 2128 (0.38) 1890 (0.34)
Neonatal death 12,074 (0.83) 400 4,829,600 2613 (0.79) 4731 (0.85) 4730 (0.84)
Birth trauma 4045 (0.28) 60 242,700 1242 (0.38) 1641 (0.29) 1162 (0.21)
NICU admissionc 61,079 (4.22) 35 2,137,765 13,199 (4.01) 23,584 (4.24) 24,296 (4.33)
Adverse Outcome Indexd 98,789 (6.83) – – 21,898 (6.66) 38,462 (6.91) 38,429 (6.84)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Weighted Adverse Outcome Score 4.86 (4.3) – – 4.52 (4.50) 5.05 (4.15) 4.97 (4.27)
Maternal age 28.86 (4.21) – – 27.43 (6.17) 29.06 (3.70) 29.83 (1.56)
Maternal comorbidity index 0.48 (0.18) – – 0.41 (0.20) 0.49 (0.17) 0.53 (0.17)
Gestational age of infant at birth in weeks 38.8 (2.0) – – 38.9 (2.0) 38.8 (2.1) 38.8 (2.1)
ICU Intensive Care Unit, MOREOB Managing Obstetrical Risk Efficiently, NICU Neonatal Intensive Care Unit
aNumber of events multiplied by the WAOS weight
b3rd degree tear data were of poor quality and therefore only 4th degree tears were included in the composite index
cNICU admission, for at least 2 days, or transfer within 24 h of birth to a facility with a NICU, for an infant with birth weight at least 2500 g
d5min Apgar not included
Table 3 Effect of implementation of MOREOB on study outcomesa, Ontario, 2002–2014
Outcome Primary analysis: Does not account for
between-hospital heterogeneity
Secondary analysis: Accounts for
between-hospital heterogeneity
WAOS, mean change (95% CI) 0.15 (−0.36 to 0.67) 0.16 (−0.41 to 0.74)
mAOI, OR (95% CI) 1.11 (1.06 to 1.17)** 1.09 (1.04 to 1.15)**
Maternal components
Maternal ICU admission 0.97 (0.75 to 1.25) 0.97 (0.75 to 1.25)
Unanticipated operative procedure 1.21 (1.05 to 1.39)** 1.26 (1.06 to 1.50)**
Blood transfusion 0.83 (0.69 to 1.00) 0.83 (0.69 to 1.00)
4th degree tear 1.36 (1.11 to 1.65)** 1.36 (1.11 to 1.65)**
Neonatal components
Neonatal death 0.97 (0.84 to 1.11) 0.84 (0.71 to 1.00)
Birth trauma 0.91 (0.75 to 1.10) 0.90 (0.75 to 1.10)
NICU admission 1.24 (1.17 to 1.32)** 1.13 (1.06 to 1.21)**
AOI Adverse Outcome Index, ICU Intensive Care Unit, MOREOB Managing Obstetrical Risk Efficiently, NICU Neonatal Intensive Care Unit, WAOS Weighted Adverse
Outcome Score
aAll analyses adjusted for calendar time, hospital annual birth volume, hospital level of care, and maternal comorbidity index; calendar time was modelled using a
restricted cubic spline function with five knots
**p < 0.05
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on the other hand, we found evidence of non-statistically
significant decreases in neonatal birth trauma and mater-
nal blood transfusion.
Comparison with previous studies
Two previous studies have assessed the effect of the im-
plementation of the MOREOB program. In the first
study, implementation of the MOREOB program in
Alberta hospitals was associated with a reduction in 3rd
and 4th degree perineal tears and decreases in maternal
length of stay and neonatal morbidity [11]. However
there were limitations to this study, including the ana-
lysis which was vulnerable to confounding by the under-
lying secular trend, as well as the short follow-up time
period. In the Alberta study only 2.8% of deliveries oc-
curred post-Module 3, whereas in our study 39% of de-
liveries occurred post-Module 3. Using a multiple
baseline interrupted time series (ITS) design, the second
study assessed the effect of MOREOB implementation on
mandatory reportable events collected by a Canadian
healthcare liability insurer [10]. In that study, the au-
thors reported a decrease of 4 mandatory reportable
events at 3 years after MOREOB implementation (95%
CI:-0.5 to 8.1) and a decrease of 8 mandatory reportable
events at 6 years post-implementation (95% CI: 1.4 to
15.1). However, this study included a smaller number of
Ontario hospitals, 34, whereas the current study in-
cluded 55 Ontario hospitals.
Other obstetric patient safety programs have been
evaluated with mixed results. A recently published rapid
review included 10 randomized controlled trials (RCT)
and reported that “provider education and other quality
improvement strategy combinations targeting healthcare
providers may improve the safety of women and their
newborns during childbirth” [7]. In an evaluation of a
program implemented at an American hospital from
2004 to 2006, it was reported that the program was asso-
ciated with a decrease in the AOI [5], as well as a de-
crease in the number of liability claims and associated
payments [4]. The nine elements of the program in-
cluded items such as the development of new protocols
and guidelines, the hiring of an Obstetric Safety Nurse,
the implementation of an Obstetric Patient Safety Com-
mittee, the involvement of Obstetric Hospitalists to pro-
vide 24-h, 7-day per week in-house coverage, as well as
team training and an electronic fetal heart rate certifica-
tion program [4, 5]. However, this program was imple-
mented at one hospital, and a simple pre/post linear
regression analysis was used, making it difficult to draw
conclusions about what the wider impact of such a pro-
gram would be. An RCT carried out at 15 American
hospitals assessing the effect of a teamwork training
program on the AOI reported no effect of the pro-
gram on this outcome [6]. Based on the literature to
date, it is difficult to conclude what elements of an
obstetric patient safety program might be most likely
to improve effectiveness.
Strengths and weaknesses
In our analytical approach, we allowed for a gradient ef-
fect of MOREOB implementation (from the first to the
final module) but thereafter, the effect of the MOREOB
program was assumed to be stable. An alternative ap-
proach may have allowed for either a gradual decay or
further gradual improvements after completion of all
modules, using, for example, an ITS approach with seg-
mented regression analysis allowing for both a step
change and a slope change. However, the staggered im-
plementation of the MOREOB program, combined with
the lengthy and variable amount of time required for
hospitals to complete the program, precluded the use of
an ITS approach. In a classical ITS analysis, the esti-
mated pre-implementation trend (secular trend) is used
to predict what the outcome event rate would have been
at the end of the study, had the intervention not been
implemented (the counterfactual estimate) [12–14].
With a long separation, using the secular trend to pre-
dict a counterfactual estimate is risky due to projection
far outside the observed range of the data.
While the staggered implementation of the MOREOB
program, which occurred over an 8 year period, pre-
sented analytic challenges, it also provided an advantage,
in that our results are less likely to be confounded by
concurrent interventions or local policy changes. Using
our multivariable model, we were essentially able to
compare outcomes from all hospitals after implementa-
tion of the program to their own pre-implementation
outcomes as well as to the outcomes from other hospi-
tals who had not yet implemented the program at the
same calendar time. As well, the use of previously devel-
oped and used [5, 6, 18–20] indicators for adverse ma-
ternal and neonatal outcomes, the mAOI and WAOS,
further strengthens our results. Given the multifaceted
nature of the MOREOB program, we considered that in-
dicators capturing multiple components of maternal/
newborn care would be more appropriate. Further, ag-
gregation of the components helps to address the rarity
of these adverse outcomes in the Canadian healthcare
setting. And, given that it had been used for research
carried out in Canada [19], this allows for the compari-
son between our estimates and what has been reported
elsewhere. The AOI rate reported by Hutcheon et al. of
5.7% is lower than the 6.8% that we report here, and the
WAOS we report is also higher (4.9 versus 1.9). It is not en-
tirely clear why these rates would differ inter-provincially
across Canada, and given the severity of these outcomes,
this might highlight an area for further research.
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We believe using composite indices as the primary
outcomes was the most appropriate choice however it is
possible that this masks the effect of the program on
specific maternal-newborn outcomes that were not
assessed by our study. As well, our analysis was limited to
the data elements available in the DAD hospitalization
database, and therefore we had to use a modified version
of the AOI, which did not include elements such as Apgar
score or 3rd degree perineal tears. Data quality is carefully
managed and documented by CIHI [27], and we made
every attempt to identify any outstanding data quality is-
sues including examining the study outcomes over time
and by hospital site, and liaising with CIHI when issues
were identified. Yet, it is possible that unidentified changes
to coding or data quality remain. Also, the occurrence of
maternal and neonatal adverse outcomes is affected by a
host of factors unrelated to participation in a program
such as the MOREOB, such as maternal age, parity and co-
morbidity. We attempted to account for this by including
hospital level of care, birth volume and a maternal comor-
bidity index in our models however, it is possible that un-
measured confounding remains. An additional limitation
was the lack of clinical performance measures in this
evaluation, such as compliance with guidelines, safety re-
ports, or documentation of near misses. Further, changes
to workplace culture were not assessed. It has previously
been reported that participation in MOREOB improved
workplace culture and increased knowledge [8], and it is
difficult to understand how improvements to workplace
culture would not result in improvements to patient out-
comes. Inclusion of objective measures of behavior such
as those described above, along with assessments of work-
place culture might help to shed light on this issue in fu-
ture studies.
Possible explanations and implications for policymakers
It is perhaps not surprising that we were unable to de-
tect an impact of the MOREOB program on a composite
indicator of adverse maternal and neonatal outcomes. In
this evaluation, which is one component of a larger
mixed-methods evaluation of the MOREOB program, we
only measured adverse outcomes. Although these are
important outcomes from the perspective of patients,
hospitals and policymakers, they cannot fully capture
other aspects of MOREOB training related to improved
communication, improvements in safety culture and in-
creases in knowledge. Our mixed-methods evaluation of
the MOREOB program also assessed individual partici-
pant responses, including care providers’ views about the
program, changes in their levels of knowledge, and their
assessments of the culture change within their organiza-
tions. Our findings from that study suggest that the
MOREOB program had a positive impact on these factors.
It is well-established that clinical behavior and practice
change takes time to become entrenched [28, 29]. As well,
when a hospital embarks on the 3-year commitment to
implement the MOREOB program, they must also find
strategies to sustain the activities and practice changes
once their dedicated funding for the program runs out. If
the activities and practice changes are not firmly estab-
lished and culture change is temporary, there may be no
detectable net benefit of the program on clinical adverse
outcomes over time. The MOREOB program does attempt
to mitigate this effect, in that it is not just an educational
program, rather every attempt is made to embed the pro-
gram within the culture of each institution. A dedicated
core team in each hospital carries out ongoing activities
related to the program [9].
Unanswered questions and future research
Improving patient safety and reducing adverse maternal
and neonatal outcomes remain issues of critical import-
ance in obstetrics, and our study demonstrates some of
the important challenges associated with this area of re-
search. Our study also demonstrates the critical nature
of large datasets and long follow-up, which is especially
important when studies are carried out in high-resource
settings where adverse outcomes are rare. Great care is
also needed in the selection of appropriate research and
analytical methods. Future studies should look at the ef-
fect of obstetrical safety programs on other adverse out-
comes such as near misses, as well as including objective
measures of behavior change.
Conclusions
We did not find improvements in a composite indicator
of adverse maternal and neonatal outcomes associated
with implementation of the MOREOB program. Future
evaluation studies should consider including other out-
comes which might better capture the effect of an ob-
stetric patient safety program.
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